These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34188004)

  • 1. Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Lauder L; Mancia G; Redon J; Schmieder RE; Sliwa K; Marx N; Weber MA; Williams B; Yusuf S; Mann JFE; Mahfoud F
    J Hypertens; 2021 Aug; 39(8):1602-1610. PubMed ID: 34188004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Emrich I; Mancia G; Redon J; Schmieder RE; Sliwa K; Lehrke M; Marx N; Weber MA; Williams B; Yusuf S; Mann JFE
    J Hypertens; 2021 Apr; 39(4):766-774. PubMed ID: 33560052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Marx N; Sliwa K; Weber MA; Williams B; Yusuf S
    Eur Heart J; 2019 Jul; 40(25):2032-2043. PubMed ID: 30919899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
    Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
    Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
    Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn E; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder R; Weber M; Sliwa K; Williams B; Yusuf S
    Eur Heart J; 2018 Sep; 39(33):3105-3114. PubMed ID: 29873709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
    Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
    Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Ukena C; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Marx N; Weber MA; Williams B; Yusuf S
    Eur Heart J; 2020 Jan; 41(2):231-238. PubMed ID: 30590564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.
    Mancia G; Schumacher H; Böhm M; Redon J; Schmieder RE; Verdecchia P; Sleight P; Teo K; Yusuf S
    Hypertension; 2017 Nov; 70(5):938-948. PubMed ID: 28974567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.
    Dans AL; Teo K; Gao P; Chen JH; Jae-Hyung K; Yusoff K; Chaithiraphan S; Zhu J; Lisheng L; Yusuf S;
    PLoS One; 2010 Dec; 5(12):e13694. PubMed ID: 21200437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.
    Verdecchia P; Reboldi G; Angeli F; Trimarco B; Mancia G; Pogue J; Gao P; Sleight P; Teo K; Yusuf S
    Hypertension; 2015 Jan; 65(1):108-14. PubMed ID: 25331850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
    Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
    J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
    Sleight P; Redon J; Verdecchia P; Mancia G; Gao P; Fagard R; Schumacher H; Weber M; Böhm M; Williams B; Pogue J; Koon T; Yusuf S;
    J Hypertens; 2009 Jul; 27(7):1360-9. PubMed ID: 19506526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
    ; Yusuf S; Teo K; Anderson C; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P
    Lancet; 2008 Sep; 372(9644):1174-83. PubMed ID: 18757085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
    Diener HC
    J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
    Mancia G; Schumacher H; Redon J; Verdecchia P; Schmieder R; Jennings G; Yusoff K; Ryden L; Liu GL; Teo K; Sleight P; Yusuf S
    Circulation; 2011 Oct; 124(16):1727-36. PubMed ID: 21947289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.